


Searching News Database: inflammation
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 28 Jul 2026
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
HSMN NewsFeed - 21 Jul 2026
Altesa BioSciences Welcomes Seasoned Biotech Leader Brett Haumann, MBBCh, MBA as Chief Executive Officer
Altesa BioSciences Welcomes Seasoned Biotech Leader Brett Haumann, MBBCh, MBA as Chief Executive Officer
HSMN NewsFeed - 20 Feb 2026
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
HSMN NewsFeed - 12 Dec 2025
Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
HSMN NewsFeed - 25 Nov 2025
Medicare Finalizes Reimbursement for Caristo's CaRi-Plaque(TM) Across Hospital and Office Settings
Medicare Finalizes Reimbursement for Caristo's CaRi-Plaque(TM) Across Hospital and Office Settings
HSMN NewsFeed - 8 Jul 2025
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
HSMN NewsFeed - 3 Jul 2025
Novartis Provides Update on Phase III GCAptAIN Study of Cosentyx(R) in Giant Cell Arteritis (GCA)
Novartis Provides Update on Phase III GCAptAIN Study of Cosentyx(R) in Giant Cell Arteritis (GCA)
HSMN NewsFeed - 23 May 2025
England's NICE Recommends FILSPARI(R) (sparsentan) as a Treatment Option for IgA Nephropathy
England's NICE Recommends FILSPARI(R) (sparsentan) as a Treatment Option for IgA Nephropathy
HSMN NewsFeed - 19 May 2025
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn(R) for ALS
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn(R) for ALS
HSMN NewsFeed - 14 Apr 2025
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
HSMN NewsFeed - 5 Sep 2024
Pfizer Appoints Elif Aral as Regional President for the Middle East, Russia & Africa
Pfizer Appoints Elif Aral as Regional President for the Middle East, Russia & Africa
HSMN NewsFeed - 19 Aug 2024
Visiox Pharmaceuticals, Inc. Announces Transformative Merger with Ocuvex Therpeutics, Inc.
Visiox Pharmaceuticals, Inc. Announces Transformative Merger with Ocuvex Therpeutics, Inc.
HSMN NewsFeed - 1 Aug 2024
Jade Biosciences Launches with $80 Million to Develop Transformative Therapies for Autoimmune Diseases
Jade Biosciences Launches with $80 Million to Develop Transformative Therapies for Autoimmune Diseases
HSMN NewsFeed - 24 Jul 2024
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
HSMN NewsFeed - 8 Jul 2024
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
HSMN NewsFeed - 17 Jun 2024
Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients
Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients
HSMN NewsFeed - 15 Dec 2023
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
HSMN NewsFeed - 13 Dec 2023
Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
HSMN NewsFeed - 6 Nov 2023
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
HSMN NewsFeed - 16 May 2023
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
HSMN NewsFeed - 27 Feb 2023
Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023
Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023
HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
HSMN NewsFeed - 23 Dec 2022
Hyphens Pharma Licenses Winlevi(R) for All 10 ASEAN countries from Cosmo Pharmaceuticals
Hyphens Pharma Licenses Winlevi(R) for All 10 ASEAN countries from Cosmo Pharmaceuticals
HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
HSMN NewsFeed - 15 Sep 2022
Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment
Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment
HSMN NewsFeed - 12 Aug 2022
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
HSMN NewsFeed - 27 Jul 2022
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
HSMN NewsFeed - 20 Jul 2022
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
HSMN NewsFeed - 21 Jun 2022
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
HSMN NewsFeed - 15 Jun 2022
RADICAVA ORS(R) (edaravone) Now Available in the U.S. for the Treatment of ALS
RADICAVA ORS(R) (edaravone) Now Available in the U.S. for the Treatment of ALS
HSMN NewsFeed - 30 Mar 2022
Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease
Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson's Disease
HSMN NewsFeed - 21 Mar 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
HSMN NewsFeed - 8 Feb 2022
Gala Therapeutics Announces First Commercial Cases Worldwide with RheOx(R) System for Chronic Bronchitis
Gala Therapeutics Announces First Commercial Cases Worldwide with RheOx(R) System for Chronic Bronchitis
HSMN NewsFeed - 3 Feb 2022
Third Pole Therapeutics Closes $25M Financing - eNOfit(TM) Wearable Device Now Ready for Clinical Trials
Third Pole Therapeutics Closes $25M Financing - eNOfit(TM) Wearable Device Now Ready for Clinical Trials
HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
HSMN NewsFeed - 8 Dec 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
HSMN NewsFeed - 7 Dec 2021
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 3 Dec 2021
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer
HSMN NewsFeed - 14 Sep 2021
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
HSMN NewsFeed - 2 Sep 2021
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
HSMN NewsFeed - 24 Aug 2021
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
HSMN NewsFeed - 5 Aug 2021
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth
HSMN NewsFeed - 15 Jul 2021
iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patients
iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patients
HSMN NewsFeed - 2 Jun 2021
Spectrum Announces Acquisition of Unique Surface Technology for Spinal Trauma
Spectrum Announces Acquisition of Unique Surface Technology for Spinal Trauma
HSMN NewsFeed - 3 May 2021
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
HSMN NewsFeed - 7 Apr 2021
FDA Approves Bausch & Lomb ClearVisc(TM) Dispersive Ophthalmic Viscosurgical Device
FDA Approves Bausch & Lomb ClearVisc(TM) Dispersive Ophthalmic Viscosurgical Device
HSMN NewsFeed - 29 Mar 2021
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
HSMN NewsFeed - 1 Feb 2021
Galderma Receives FDA Approval for Restylane(R) Defyne for Chin Augmentation
Galderma Receives FDA Approval for Restylane(R) Defyne for Chin Augmentation
HSMN NewsFeed - 28 Jan 2021
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
HSMN NewsFeed - 11 Jan 2021
CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing
CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing
HSMN NewsFeed - 8 Jan 2021
Blacksmith Medicines Launches With Seed Funding and a Research Collaboration With Lilly
Blacksmith Medicines Launches With Seed Funding and a Research Collaboration With Lilly
HSMN NewsFeed - 6 Jan 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
HSMN NewsFeed - 22 Dec 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
HSMN NewsFeed - 1 Dec 2020
Novartis announces FDA approval of Xolair(R) (omalizumab) for adults with nasal polyps
Novartis announces FDA approval of Xolair(R) (omalizumab) for adults with nasal polyps
HSMN NewsFeed - 16 Nov 2020
iSTAR Medical's glaucoma device MINIject shows positive one-year results in European trial
iSTAR Medical's glaucoma device MINIject shows positive one-year results in European trial
HSMN NewsFeed - 12 Nov 2020
Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases
Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases
HSMN NewsFeed - 3 Nov 2020
Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. as Chief Executive Officer
Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. as Chief Executive Officer
HSMN NewsFeed - 26 Oct 2020
Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
HSMN NewsFeed - 22 Oct 2020
CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis
CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis
HSMN NewsFeed - 19 Oct 2020
Solarea Bio Announces Series A Financing Led by S2G Ventures and Bold Capital Partners
Solarea Bio Announces Series A Financing Led by S2G Ventures and Bold Capital Partners
HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 19 Jun 2020
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
HSMN NewsFeed - 4 Jun 2020
Mylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
Mylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
HSMN NewsFeed - 27 May 2020
Acquist Therapeutics Announces New Appointments to its Board of Directors
Acquist Therapeutics Announces New Appointments to its Board of Directors
HSMN NewsFeed - 15 May 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
HSMN NewsFeed - 13 May 2020
Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer
Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer
HSMN NewsFeed - 27 Apr 2020
Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
HSMN NewsFeed - 13 Apr 2020
U.S. FDA Grants CytoSorb(R) Emergency Use Authorization for Use in Patients with COVID-19 Infection
U.S. FDA Grants CytoSorb(R) Emergency Use Authorization for Use in Patients with COVID-19 Infection
HSMN NewsFeed - 26 Mar 2020
Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte(R) RAPID
Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte(R) RAPID
HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
HSMN NewsFeed - 17 Jan 2020
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR(R)
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR(R)
HSMN NewsFeed - 7 Jan 2020
IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer
IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 1 Nov 2019
CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom
CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom
HSMN NewsFeed - 18 Sep 2019
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
HSMN NewsFeed - 16 Sep 2019
Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning
Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning
HSMN NewsFeed - 4 Sep 2019
Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx(TM) System for Chronic Bronchitis
Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx(TM) System for Chronic Bronchitis
HSMN NewsFeed - 30 Jul 2019
Alfa Plus by Solio Receives FDA Clearance: Unique Device Delivers Pain Relief Without Pharmaceuticals
Alfa Plus by Solio Receives FDA Clearance: Unique Device Delivers Pain Relief Without Pharmaceuticals
HSMN NewsFeed - 8 Jul 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
HSMN NewsFeed - 12 Jun 2019
Zyla Life Sciences Appoints Dr. H. Jeffrey Wilkins as Chief Medical Officer
Zyla Life Sciences Appoints Dr. H. Jeffrey Wilkins as Chief Medical Officer
HSMN NewsFeed - 30 May 2019
Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA
Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA
HSMN NewsFeed - 30 Apr 2019
Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing
Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing
HSMN NewsFeed - 23 Apr 2019
Akero Therapeutics Appoints Industry Veteran Jane Pritchett Henderson to Board of Directors
Akero Therapeutics Appoints Industry Veteran Jane Pritchett Henderson to Board of Directors
HSMN NewsFeed - 25 Mar 2019
Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor
Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor
HSMN NewsFeed - 13 Mar 2019
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
HSMN NewsFeed - 19 Feb 2019
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
HSMN NewsFeed - 29 Jan 2019
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
HSMN NewsFeed - 3 Jan 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
HSMN NewsFeed - 11 Dec 2018
LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy
LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy
HSMN NewsFeed - 14 Nov 2018
Grünenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US
Grünenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US
HSMN NewsFeed - 5 Nov 2018
Galderma Announces FDA Approval of Restylane(R) Lyft For Midface Injection via Cannula
Galderma Announces FDA Approval of Restylane(R) Lyft For Midface Injection via Cannula
HSMN NewsFeed - 25 Oct 2018
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
HSMN NewsFeed - 13 Sep 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
HSMN NewsFeed - 17 Aug 2018
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
HSMN NewsFeed - 31 Jul 2018
Natera Appoints Roy Baynes to Board of Directors, Adding Deep Oncology Experience
Natera Appoints Roy Baynes to Board of Directors, Adding Deep Oncology Experience
HSMN NewsFeed - 24 Jul 2018
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
HSMN NewsFeed - 13 Jul 2018
Kypha Acquires Biosensia - Expands First-in-Class Immune Status Monitoring Platforms
Kypha Acquires Biosensia - Expands First-in-Class Immune Status Monitoring Platforms
HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
HSMN NewsFeed - 4 Jun 2018
AOBiome Therapeutics Announces Election of Dr. Jun Wang as Chairman of the Board of Directors
AOBiome Therapeutics Announces Election of Dr. Jun Wang as Chairman of the Board of Directors
HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
HSMN NewsFeed - 10 May 2018
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
HSMN NewsFeed - 8 May 2018
Pliant Therapeutics Appoints Hoyoung Huh as Chairman and Éric Lefebvre as Chief Medical Officer
Pliant Therapeutics Appoints Hoyoung Huh as Chairman and Éric Lefebvre as Chief Medical Officer
HSMN NewsFeed - 3 May 2018
Topix Pharmaceuticals Launches Game Changing Treatment Cream For Extremely Dry Skin
Topix Pharmaceuticals Launches Game Changing Treatment Cream For Extremely Dry Skin
HSMN NewsFeed - 1 May 2018
Pharmaceutical Business Development Leader Dr. Kevin Lynch Joins Recursion as Chief Business Officer
Pharmaceutical Business Development Leader Dr. Kevin Lynch Joins Recursion as Chief Business Officer
HSMN NewsFeed - 26 Apr 2018
Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)
Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)
HSMN NewsFeed - 25 Apr 2018
Dermtreat Appoints Nishan de Silva, M.D., as CEO; Establishes North American Headquarters in San Diego
Dermtreat Appoints Nishan de Silva, M.D., as CEO; Establishes North American Headquarters in San Diego
HSMN NewsFeed - 24 Apr 2018
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
HSMN NewsFeed - 20 Apr 2018
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
HSMN NewsFeed - 3 Apr 2018
Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
HSMN NewsFeed - 2 Apr 2018
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
HSMN NewsFeed - 7 Feb 2018
UNITY Biotechnology Adds Accomplished R&D Leader David L. Lacey, M.D., to Board of Directors
UNITY Biotechnology Adds Accomplished R&D Leader David L. Lacey, M.D., to Board of Directors
HSMN NewsFeed - 1 Feb 2018
Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO
Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO
HSMN NewsFeed - 23 Jan 2018
TECHLAB Receives FDA 510(k) Clearance To Market CAMPYLOBACTER QUIK CHEK(TM) and CAMPYLOBACTER CHEK(TM) Tests
TECHLAB Receives FDA 510(k) Clearance To Market CAMPYLOBACTER QUIK CHEK(TM) and CAMPYLOBACTER CHEK(TM) Tests
HSMN NewsFeed - 22 Jan 2018
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
HSMN NewsFeed - 10 Jan 2018
New Kleiner Spine Graft Delivery Tool Improves Outcomes for Patients, Surgeons, Hospitals and Payers
New Kleiner Spine Graft Delivery Tool Improves Outcomes for Patients, Surgeons, Hospitals and Payers
HSMN NewsFeed - 3 Jan 2018
Inova Diagnostics Receives FDA Clearance for the First Fully Automated, Random Access Calprotectin Test
Inova Diagnostics Receives FDA Clearance for the First Fully Automated, Random Access Calprotectin Test
HSMN NewsFeed - 21 Dec 2017
Santen Receives Complete Response Letter from U.S. FDA for Intravitreal Sirolimus (DE-109)
Santen Receives Complete Response Letter from U.S. FDA for Intravitreal Sirolimus (DE-109)
HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
HSMN NewsFeed - 7 Dec 2017
Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development
Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development
HSMN NewsFeed - 5 Dec 2017
Cocoon Biotech Appoints Dr. Annalisa Jenkins as Executive Chair of the Board
Cocoon Biotech Appoints Dr. Annalisa Jenkins as Executive Chair of the Board
HSMN NewsFeed - 4 Dec 2017
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
HSMN NewsFeed - 1 Dec 2017
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
HSMN NewsFeed - 30 Nov 2017
Fractyl Completes $44 Million Series D Financing to Advance New Treatment for Type 2 Diabetes
Fractyl Completes $44 Million Series D Financing to Advance New Treatment for Type 2 Diabetes
HSMN NewsFeed - 13 Nov 2017
PlaqueTec Announces the Appointment of Annalisa Jenkins, MBBS, FRCP, as Chief Executive Officer
PlaqueTec Announces the Appointment of Annalisa Jenkins, MBBS, FRCP, as Chief Executive Officer
HSMN NewsFeed - 25 Oct 2017
Sobi: Alprolix(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
Sobi: Alprolix(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
HSMN NewsFeed - 20 Oct 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
HSMN NewsFeed - 6 Oct 2017
Norbert Oppitz Joins Sobi(TM) as New Senior Vice President, Specialty Care
Norbert Oppitz Joins Sobi(TM) as New Senior Vice President, Specialty Care
HSMN NewsFeed - 28 Sep 2017
Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA(TM)
Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA(TM)
HSMN NewsFeed - 20 Sep 2017
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
HSMN NewsFeed - 15 Aug 2017
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
HSMN NewsFeed - 14 Aug 2017
Synthorx Appoints Marcos Milla, Ph.D. as Senior Vice President of Research
Synthorx Appoints Marcos Milla, Ph.D. as Senior Vice President of Research
HSMN NewsFeed - 21 Jul 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
HSMN NewsFeed - 17 Jul 2017
Phoenix Molecular Designs Appoints Leading Oncology Expert Dr. Gerrit Los as Chief Scientific Officer
Phoenix Molecular Designs Appoints Leading Oncology Expert Dr. Gerrit Los as Chief Scientific Officer
HSMN NewsFeed - 3 Jul 2017
BIOTRONIK US Announces Pivotal Trial Results of the Pulsar-18 Stent with 4-French Delivery System
BIOTRONIK US Announces Pivotal Trial Results of the Pulsar-18 Stent with 4-French Delivery System
HSMN NewsFeed - 30 Jun 2017
Xiapex(R) Gets Recommendation to be Made Available on National Health Service in England
Xiapex(R) Gets Recommendation to be Made Available on National Health Service in England
HSMN NewsFeed - 23 May 2017
IFM Therapeutics Appoints H. Martin Seidel as Executive Vice President of Research and Development
IFM Therapeutics Appoints H. Martin Seidel as Executive Vice President of Research and Development
HSMN NewsFeed - 17 May 2017
Xeltis' Technology for Natural Heart Valve Restoration Featured as the Future of Valve Therapy at EuroPCR
Xeltis' Technology for Natural Heart Valve Restoration Featured as the Future of Valve Therapy at EuroPCR
HSMN NewsFeed - 15 May 2017
Nuvo Pharmaceuticals(TM) Inc. Announces Topline Results from European Ankle Sprain Study with Pennsaid(R) 2%
Nuvo Pharmaceuticals(TM) Inc. Announces Topline Results from European Ankle Sprain Study with Pennsaid(R) 2%
HSMN NewsFeed - 2 May 2017
Imprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears(TM)
Imprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears(TM)
HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
HSMN NewsFeed - 26 Apr 2017
Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
HSMN NewsFeed - 18 Apr 2017
Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
HSMN NewsFeed - 7 Apr 2017
Flexion Therapeutics Announces Appointment of Yamo Deniz, MD, as Chief Medical Officer
Flexion Therapeutics Announces Appointment of Yamo Deniz, MD, as Chief Medical Officer
HSMN NewsFeed - 29 Mar 2017
Tepha Inc. Subsidiary, Galatea Surgical, Announces Launch of GalaSHAPE(TM) 3D Surgical Scaffold
Tepha Inc. Subsidiary, Galatea Surgical, Announces Launch of GalaSHAPE(TM) 3D Surgical Scaffold
HSMN NewsFeed - 28 Mar 2017
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
HSMN NewsFeed - 24 Mar 2017
Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
HSMN NewsFeed - 24 Mar 2017
Reata Pharmaceuticals, Inc. Appoints David Chapman as Vice President, Marketing
Reata Pharmaceuticals, Inc. Appoints David Chapman as Vice President, Marketing
HSMN NewsFeed - 6 Mar 2017
Izun Pharmaceuticals Announces Approval of Curasite(TM) Hydrogel Wound Care Product by FDA
Izun Pharmaceuticals Announces Approval of Curasite(TM) Hydrogel Wound Care Product by FDA
HSMN NewsFeed - 16 Feb 2017
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Additional items found! 500
Members Archive contains
500 additional stories matching:
inflammation
(Password required)
inflammation
(Password required)
